

NOURIANZ (istradefylline, oral)

Diagnosis Considered for Coverage:

- Parkinson's disease (PD) in patients experiencing 'off' episodes

Coverage Criteria:

For diagnosis listed above:

- Inadequate response, intolerable side effect, or contraindication with TWO drug classes for used to reduce Parkinson's disease "off" episodes including:
 - Dopamine agonists (e.g. pramipexole, ropinirole, bromocriptine),
 - COMT inhibitors (e.g. entacapone, tolcapone),
 - MAO-B inhibitors (e.g. rasagiline, selegiline),
 - Amantadine (Symmetrel), **and**
- Dose does not exceed FDA label maximum.

Coverage Duration: one year

Effective Date: 11/30/2022